Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression
AssigneeLife Technologies Corporation
InventorsRonald Levy, Mark A. Wechser, Izidore S. Lossos, Robert J. Tibshirani, Ash A. Alizadeh, David Botstein
Life of this patent
Estimating the term…
Abstract
Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
Claims15
1-13. (canceled)
A kit comprising:
- real time PCR assays for measuring expression of a plurality of genes in a sample from a patient having DLBCL;
- wherein normalized expression of a plurality of genes in samples from DLBCL patients stratifies said DLBCL patients into classification groups, wherein said normalized expression of said plurality of genes classify said DLBCL patients in groups predictive of probability of survival;
- wherein said plurality of genes consists essentially of LMO2, BCL-6, FN1, CCND2, SCYA3 and BCL-2.
24-44. (canceled)
Dependencies are inferred from the claim text.